CERS CRIS CGEN CPHD – 4 Fab Biotech Stocks on the Fast Track

Continued upside potential for this sector

      View All  
CERS CRIS CGEN CPHD – 4 Fab Biotech Stocks on the Fast Track

Curis

Curis (CRIS) is a small cancer treatment company with novel technology already approved for one malady – advanced melanoma – and with more than 20 trials underway through powerful partners – Roche/Genentech and the National Cancer Institute. The core technology disrupts inter-cellular communications during the cell duplication process, preventing or slowing the growth of cancer cells. Advanced melanoma is a narrow indication; if the company’s approach is approved for a treatment for a solid tumor type, such as colon cancer, this will be further proof of concept for the technology and the stock should explode.


Article printed from InvestorPlace Media, http://investorplace.com/2013/11/biotech-stocks-cers-cris-cgen-cphd/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.